MiMedx Group (MDXG) AI Stock Analysis

• Market Cap: $716.09M
• Dividend Yield: N/A
• Average Volume (3M): 963.25K
• Price to Earnings (P/E): 20.6
• Beta (1Y): 0.65
• Revenue Growth: 14.77%
• EPS Growth: -58.90%
• Country: US
• Employees: 837
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.10
• Shares Outstanding: 148,566,590
• 10 Day Avg. Volume: 1,018,055
• 30 Day Avg. Volume: 963,249
• PEG Ratio: 1.49
• Price to Book (P/B): 3.90
• Price to Sales (P/S): 2.39
• P/FCF Ratio: 13.71
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 1.31
• Enterprise Value/Gross Profit: 1.59
• Enterprise Value/Ebitda: 6.75
• 1Y Price Target: $9.60
• Price Target Upside: 101.68% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): 0.11
• Revenue Forecast (FY): $357.16M

• Rating: 73 Outperform
• Price Target: $6.00 ▲(26.05% Upside)
• Action: Reiterated Date: 02/26/26
• Date: Action: Reiterated 02/26/26

The score is driven primarily by strong financial performance (improving profitability, robust cash generation, and a very conservative balance sheet). The earnings call supports the fundamental trend with raised growth guidance and strong margins, but the technical picture is a headwind (below key longer-term moving averages with negative MACD), and valuation is only moderate with no dividend yield data.

Positive Factors

Balance sheet strength

MiMedx's extremely low net debt and enlarged equity base provide durable financial flexibility. A conservative balance sheet supports continued investment in commercial expansion, clinical programs, and M&A optionality while buffering the company through reimbursement or demand shifts over the next 2–6 months.

Cash generation / free cash flow

Sustained positive operating and free cash flow in 2024–2025 signals durable cash conversion versus prior loss years. Reliable FCF enables reinvestment in sales/clinical evidence and funds working capital or strategic initiatives without reliance on external financing, supporting long-term operational stability.

High product-level margins

Consistently high gross margins reflect strong product economics for placental-derived biologics and pricing power in wound and surgical markets. Durable product-level margins underpin sustainable EBITDA conversion and provide room to absorb below-the-line variability or targeted commercial investments.

Negative Factors

Medicare reimbursement reform risk

Anticipated Medicare reimbursement changes beginning in 2026 pose a structural revenue and margin risk for clinician-delivered biologics. Reduced coverage or lower fees could materially alter uptake and hospital/procurement economics across sites of care, changing demand dynamics over the medium term.

Ongoing legal and regulatory costs

Persistent litigation and regulatory spending are a durable drag on margins and management bandwidth. Recurrent legal costs limit FCF allocation to growth initiatives and introduce settlement or operational risk that can persist for multiple quarters, reducing capital available for commercialization or trials.

Historical earnings and cash-flow volatility

Prior multi-year volatility in profitability and cash flow indicates the business is sensitive to adoption, sourcing or reimbursement shifts. While recent years show improvement, the track record suggests risk that earnings and cash conversion could revert under adverse market or regulatory conditions.

MiMedx Group Business Overview & Revenue Model

Company Description

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

How the Company Makes Money

MiMedx generates revenue primarily through the sale of its allograft tissue products. The company sells these products to hospitals, outpatient surgical centers, and other healthcare providers. Revenue streams are largely derived from the distribution of its advanced wound care and orthopedic solutions, with a significant emphasis on the management of chronic wounds such as diabetic foot ulcers and venous leg ulcers. MiMedx has established partnerships with various healthcare organizations and distributors, which enhance its market reach and customer base. The company's financial performance is also influenced by trends in healthcare spending, the adoption of regenerative medicine, and the regulatory environment surrounding tissue-based therapies.

MiMedx Group Financial Statement Overview

Summary

Strong multi-year turnaround with rising revenue (2025 $418.6M vs. 2024 $348.9M), consistently high gross margins (~82–83%), solid profitability in 2024–2025 (~12% net margin), and improving operating/free cash flow (2025 OCF/FCF ~$74M). Balance sheet is a major strength with minimal debt (~$1.5M) versus equity (~$256.5M), though prior-year variability and some operating-profitability inconsistency remain watch items.

Income Statement

Profitability and growth have improved materially versus the 2020–2022 loss-making period. Revenue rose to $418.6M in 2025 (annual) from $348.9M in 2024, with very strong gross margins holding steady around ~82–83%. Net margins are solidly positive in 2024–2025 (~12%), though they are below the 2023 peak and operating profitability looks less consistent year-to-year (including an apparent anomaly in 2025 EBIT margin data). Overall, the income statement reflects a strong turnaround and resilient product-level economics, with some variability in below-the-line profitability.

Balance Sheet

The balance sheet strengthened significantly, highlighted by very low leverage in 2025 with total debt of ~$1.5M against stockholders’ equity of ~$256.5M (debt-to-equity ~0.01). Equity has expanded meaningfully from 2020–2022 levels, and returns on equity are strong in 2024–2025 (~19–22%), indicating improved earnings power on a larger capital base. A key watch item is that leverage was higher in earlier years (notably 2022), but the current balance sheet profile is conservatively positioned.

Cash Flow

Cash generation is strong and improving: operating cash flow increased to ~$74.0M in 2025 (annual) from ~$66.2M in 2024, with free cash flow also at ~$74.0M and positive growth. Cash flow quality is good, with operating cash flow exceeding net income in 2024–2025 (coverage ~1.15–1.45), supporting earnings durability. The main weakness is the historical volatility—cash flow was negative in 2020–2022 and coverage was weak in 2023—though the most recent two years show sustained positive conversion.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	418.63M	348.88M	321.48M	267.84M	242.02M
Gross Profit	345.62M	288.81M	266.84M	219.53M	202.39M
EBITDA	82.93M	65.35M	40.54M	-10.68M	-1.89M
Net Income	48.58M	42.42M	67.44M	-30.20M	-12.30M
Balance Sheet
Total Assets	342.65M	263.92M	239.05M	171.43M	187.93M
Cash, Cash Equivalents and Short-Term Investments	166.12M	104.42M	82.00M	65.95M	87.08M
Total Debt	1.50M	24.84M	48.10M	52.47M	53.29M
Total Liabilities	86.11M	70.81M	96.33M	96.92M	95.35M
Stockholders Equity	256.55M	193.11M	142.72M	74.51M	92.58M
Cash Flow
Free Cash Flow	72.97M	64.52M	24.79M	-19.41M	-5.20M
Operating Cash Flow	74.00M	66.20M	26.77M	-17.89M	-1.98M
Investing Cash Flow	-6.89M	-9.58M	-2.15M	-2.66M	-3.40M
Financing Cash Flow	-5.41M	-34.20M	-8.57M	-580.00K	-3.35M

MiMedx Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MDXG, the sentiment is Negative. The current price of 4.76 is below the 20-day moving average (MA) of 5.10, below the 50-day MA of 5.64, and below the 200-day MA of 6.55, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 32.05 is Neutral, neither overbought nor oversold. The STOCH value of 15.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MDXG.

MiMedx Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDXG	73 Outperform	$716.09M	20.60	21.61%	―	14.77%	-58.90%
MAZE	68 Neutral	$2.13B	-9.86	-36.13%	―	―	―
PHAR	58 Neutral	$1.12B	32.13	0.44%	―	26.54%	―
ORIC	57 Neutral	$1.36B	-5.55	-41.27%	―	―	4.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ATAI	48 Neutral	$1.34B	-4.71	―	―	―	―

MiMedx Group Corporate Events

MiMedx Group Updates Strategy in Wound Care Markets

On January 12, 2026, MiMedx Group updated its investor presentation, highlighting its strategy to drive growth in the sizeable wound care and surgical markets through innovation in placental-derived products, expanded clinical evidence, and disciplined capital allocation. The materials emphasize ongoing and planned clinical studies across multiple surgical specialties, the significant unmet medical and economic burden of chronic wounds and postoperative complications such as colorectal anastomotic leaks, and the company’s focus on leveraging its product portfolio and strong balance sheet to support continued revenue growth, profitability, and potential expansion via M&A, with implications for reinforcing its competitive position and value creation objectives for stakeholders.

The most recent analyst rating on (MDXG) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on MiMedx Group stock, see the MDXG Stock Forecast page.